

Antianemic agents

Antianemic agents are used in cases where we need to increase the hematopoiesis.

Iron

The reference range of serum iron = 10,0–27,0 $\mu\text{mol/l}$. Iron deficiency anemia is expected predominately in:

- neonates, pre-term newborns,
- pregnant and breast-feeding woman,
- patients with small bowel disease,
- with increased blood loss to gastrointestinal tract, during metrorrhagia, blood donors.

Acute iron intoxication

The signs and symptoms are necrotising gastroenteritis with vomiting, stomach ache, diarrhea with bleeding, shock, lethargy and dyspnea. After mild improvement, there is severe metabolic acidosis, coma and death. It is very dangerous in children - we need to store them beyond their reach. The therapy is based on thorough gastric emptying and lavage phosphate or carbonate solutions. They form with iron non-absorbable complexes. Then we proceed with administration of *deferoxaminu* (i.m. or i.v.). It is a chelator agent which binds remaining iron in the gut.

Chronic iron intoxication

Is called hemochromatosis or hemosiderosis. It leads to storage of iron in heart, liver and pancreas.

Peroral therapy

It is designated for long-term therapy: 3–6 months. It is well tolerated in most of the patients.

Negative side effects

Nausea, abdominal cramps, constipation, diarrhea, black stool (with no clinical significance). These symptoms can be removed by lowering the dose.

Parenteral therapy

It is used in patients with malabsorption syndrome, with large blood loss etc.

For further information see Iron

Vitamin B12 (cyanocobalamin)

It is not synthesized by plants or animals. It is produced by microbial activity in digestive system or it is delivered to the organism with food containing milk, meat and eggs. It is absorbed after forming a complex with intrinsic factor (glykoprotein) - this complex is absorbed in distal ileum after binding to receptors with highly specific transport system.

They are used in therapy only in cases of its deficiency - for example in patients with pernicious anemia (in patients with normal level its administration has no value).

Considering fact, that most of the patients have a failure to absorb B12, we need to treat this condition by its administration via parenteral route (by injection) - in irreversible cause of deficiency the lifelong therapy is necessary; reversible disorders leading to B12 deficiency are treated after the vitamin treatment is finished.


Negative side effects: rare - acne, allergic skin reaction, even with high doses there were not seen any toxic effects.

For further information see Vitamin B12

Folic acid (acidum folicum, vitamin B9)

It is synthesized by plants and microorganisms = intake with food (meat - liver, kidney, yeast, leaf vegetable).

Folic acid deficiency is often caused by its lower intake in food, for example: the elderly, the poor, the ill (tumors, leukemia, skin diseases, chronic disease), pregnant woman, patients with hemolytic anemia (increased demand) - folate deficiency in mothers can be harmful to fetus (spina bifida), medication interacting with absorption or folate metabolism (phenytoin, isoniazid, some anticonvulsants and contraceptives inhibits the conjugases in gut; methotrexate, trimethoprim inhibits dihydrofolate reductase, barbiturates).




Vitamin B12

They are administered in p.o. (pills) – good absorption and tolerance.

For further information see Folic acid (vitamin B9)

Vitamin B6 (pyridoxin)

For further information see Vitamin B6 (pyridoxin)



Copper

For further information see Copper.

Cobalt

- Essential element which is a part of vitamin B12.

Hematopoietic growth factors

- Agents with glycoprotein hormone properties, which influence the production and differentiation of red blood cells in the bone marrow, some of them are:
 - **erythropoietin** (EPO),
 - **granulocyte growth factor** (G-CSF),
 - **monocyte-macrophage growth factor** (M-CSF),
 - **granulocyte-macrophage growth factor** (GM-CSF),
 - **interleukin 3**.

Other agents

Anabolics

- They stimulate the hematopoiesis by increasing the production of erythropoietin (↑ erythrocytů).
- *Indication:* aplastic anemia, myelofibrosis and myelodysplastic syndrome.
- **Nandrolon**.

Corticosteroids

- They have impact on the hematopoiesis.
- *Indication:* autoimmune disease affecting the hematopoiesis (autoimmune hemolytic anemia, thrombocytopenia, neutropenia), blood malignancies.
- **Methylprednisolone, prednisone**.

Links

Literature

- MARTÍNKOVÁ, Jiřina, Stanislav MIČUDA a Jolana ČERMÁKOVÁ. *Vybrané kapitoly z klinické farmakologie pro bakalářské studium : Terapie anémií* [online]. ©2001. [cit. 2010-07-08]. <<http://www.lfhk.cuni.cz/farmakol/predn/bak/kapitoly/anemie-bak.doc>>.
-

Related articles

- Anémie
- Posthemorhagická anémie
- Hemolytická anémie
- Anémie megaloblastové
- Anémie ze snížené tvorby erythrocytů